These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 33978711)

  • 1. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
    JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
    Silverberg JI; Simpson EL; Thyssen JP; Werfel T; Cardillo TE; Colvin S; Pierce E; Chen YF; Chen S; Eichenfield L
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1036-1045. PubMed ID: 36514996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
    Silverberg JI; Boguniewicz M; Waibel J; Weisman J; Strowd L; Sun L; Ding Y; Feely M; Nunes FP; Simpson EL
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):137-148. PubMed ID: 34846636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Reich K; Simpson E; Wollenberg A; Bissonnette R; Abe M; Cardillo T; Janes J; Sun L; Chen S; Silverberg JI
    Br J Dermatol; 2023 Feb; 188(2):208-217. PubMed ID: 36763879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
    Thyssen JP; Werfel T; Barbarot S; Hunter HJA; Pierce E; Sun L; Cirri L; Buchanan AS; Lu N; Wollenberg A
    J Dermatolog Treat; 2023 Dec; 34(1):2190430. PubMed ID: 36912484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
    JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
    Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
    J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
    Wollenberg A; Lio P; Kleyn E; Bissonnette R; Jose Rueda M; Casillas M; Chen YF; Lu N; Schloebe A; Simpson E
    Eur J Dermatol; 2022 Jul; 32(4):522-529. PubMed ID: 36301752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
    Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
    Bieber T; Thyssen JP; Irvine AD; Tsunemi Y; Chen YF; Sun L; Schloebe A; Riedl E; Cork MJ
    Clin Exp Dermatol; 2023 Jul; 48(8):881-888. PubMed ID: 37032446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
    Simpson EL; Bissonnette R; Paller AS; King B; Silverberg JI; Reich K; Thyssen JP; Doll H; Sun L; DeLozier AM; Nunes FP; Eichenfield LF
    Br J Dermatol; 2022 Oct; 187(4):531-538. PubMed ID: 35442530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes.
    Simpson E; Armstrong A; Boguniewicz M; Chiesa Fuxench ZC; Feely M; Pierce E; Sun L; Chen YF; Angle R; Silverberg JI
    Dermatol Ther; 2022 Dec; 35(12):e15954. PubMed ID: 36270978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
    Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL; Lacour JP; Spelman L; Galimberti R; Eichenfield LF; Bissonnette R; King BA; Thyssen JP; Silverberg JI; Bieber T; Kabashima K; Tsunemi Y; Costanzo A; Guttman-Yassky E; Beck LA; Janes JM; DeLozier AM; Gamalo M; Brinker DR; Cardillo T; Nunes FP; Paller AS; Wollenberg A; Reich K
    Br J Dermatol; 2020 Aug; 183(2):242-255. PubMed ID: 31995838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Thyssen JP; Buhl T; Fernández-Peñas P; Kabashima K; Chen S; Lu N; DeLozier AM; Casillas M; Ständer S
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1599-1611. PubMed ID: 34275122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D; Fretzin S; Strowd L; Casillas M; DeLozier AM; Dawson Z; Chen S; Lu N; Thyssen JP
    J Cutan Med Surg; 2022; 26(4):377-385. PubMed ID: 35354410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.
    Thyssen JP; de Bruin-Weller M; Costanzo A; Grond S; Schuster C; Liu C; Rueda MJ; Chen YF; Pinter A; Bieber T
    Adv Ther; 2023 Aug; 40(8):3574-3587. PubMed ID: 37332021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.